Research has shown that melatonin inhibits Aβ aggregation in astrocytes derived from transgenic AD mice overexpressing APOE4 [49], indicating that exogenous melatonin could be especially beneficial for AD patients with this genetic profile. Here, APOE is linked to Alzheimer disease.